Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Nivolumab and nab-Paclitaxel in Advanced Cancers
NCT02309177Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2015
- Primary completion
- Sep 2018
- Modality
- Polymer-based Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nab-paclitaxel and nivolumab in pancreatic adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and breast cancer (6 arms), sponsored by Celgene Corporation. Primary endpoints: Dose Limiting Toxicity at 24 months, Safety of combination regimens at 44 months and 1 more. Started Jan 2015; status: completed.
02
Drugs
nab-paclitaxelnivolumab
03
Conditions
pancreatic adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT02309177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02309177.